Gitnux/Report 2026

Nad Plus Industry Statistics

The global NAD+ supplements market is estimated at $3.2 billion in 2026, explore how double-digit growth, Asia-Pacific share, and label-accuracy issues shape company comparisons and product scrutiny.
15Statistics
21Sources
4Sections
1Visuals
14mRead
Nad Plus Industry Statistics
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The nad plus industry at a glance

The global NAD+ supplements market is estimated at $3.2 billion in 2026, with demand led by healthy-aging products, while clinical evidence and product-quality concerns remain significant industry constraints.

$3.2B[1]
Global market estimate, 2026
14.8%[1]
Global CAGR, 2026–2033
49.0%[1]
Asia-Pacific share, 2025
61.1%[1]
Capsules/tablets share, 2025
Market size
The global nicotinamide adenine dinucleotide supplements market was valued at $2.8 billion in 2025 and is estimated at $3.2 billion in 2026. The U.S. market is estimated at $263.8 million in 2025, although the supplier identifies this as a placeholder estimate rather than a researched figure.[1][9]
Forecast & CAGR
Grand View Research forecasts the global market to reach $8.5 billion by 2033, implying a 14.8% CAGR from 2026 to 2033. Acuitas Health Analytics estimates U.S. growth at 9.1% annually from 2025 to 2034, reaching $577.6 million, but labels its figures as placeholders.[1][9]
Market share & regions
Asia-Pacific was the largest regional market in 2025, accounting for 49.0% of global revenue, with China reported as the leading country market. Middle East and Africa is forecast to be the fastest-growing region, with a projected 15.1% CAGR from 2026 to 2033.[1]
Segmentation
Capsules and tablets held 61.1% of global revenue in 2025, while online distribution accounted for 48.3%. The market is also segmented by ingredient, including nicotinamide riboside, nicotinamide mononucleotide and direct NAD+ products, and by gummies, powders and other delivery formats.[1][9]
Key players & concentration
Named U.S. competitors include Niagen Bioscience, formerly ChromaDex, Elysium Health, Thorne, Life Extension and Renue By Science. Acuitas Health Analytics characterizes the U.S. market as moderately concentrated, with competition focused on formulation, clinical evidence, pricing and distribution reach.[9]
Trends, drivers & challenges
Growth is being driven by healthy-aging demand, preventive wellness, e-commerce and interest in cellular energy. Product-quality and evidence gaps remain material: in a 2026 analysis of 27 top-selling Amazon products labeled as containing NAD+, only 6 products, or 22%, met or exceeded their label claim, while 13 products, or 48%, contained less than 1% of the claimed NAD+ amount.[1][3]
Consumer behavior & competition
The Vitamin Shoppe reported that 75% of surveyed Americans were very or somewhat concerned about aging’s impact on their health in 2025, while taking vitamins and supplements was cited as the most popular longevity activity by 43% of respondents. Life Extension was its NAD+ sales leader, with Q1 2025 sales growth of 127%, and searches for NAD+ on VitaminShoppe.com rose nearly 500% during the year.[10]
M&A
In December 2025, Niagen Bioscience acquired Queen’s University Belfast’s existing core nicotinamide riboside patent portfolio, making the company the sole owner of the acquired intellectual property. The company reported more than 90 issued and pending patents worldwide across NR and other NAD+ precursors, including more than 50 focused solely on NR.[11]
Regulation
In the United States, dietary supplements do not require FDA approval before sale, but the FDA can act against unsafe or misbranded products. Compounded drugs are not FDA-approved, and NAD+ is not FDA-approved for a specific medical indication; the FDA states that compounded drugs are not reviewed for safety, effectiveness or quality before marketing.[9][12][13]
Latest news
In August 2026, Niagen Bioscience expanded Tru Niagen’s U.S. retail presence through GNC and Sam’s Club, reaching nearly 300 locations across 44 states and offering multiple product formats. The move illustrates the category’s shift from direct-to-consumer sales toward broader specialty and mass retail distribution.[1]

02 Ranking

Top 4 Companies in the Nad Plus Industry

The leading companies in the nad plus industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

BONTAC stands out for NAD+ related ingredient manufacturing because it produces NAD, NADH, NMN, NMNH and NR using proprietary enzymatic production methods, while MetroBiotech focuses on NAD+ precursor development since it develops MIB-626 and other proprietary NAD+ precursors for age-related diseases.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in NAD+ ingredient production

    BONTAC

    CN

    Ranked #1 · 9.4 · NAD+ ingredient production

    Why we picked it: It manufactures NAD+ related ingredients at scale through proprietary enzymatic production methods across NAD, NADH, NMN, NMNH and NR.

  2. Leader in NAD+ precursor development

    MetroBiotech

    US

    Ranked #2 · 8.7 · NAD+ precursor development

    Why we picked it: It develops NAD+ precursors for age-related diseases, centered on its proprietary MIB-626 program.

  3. Leader in NR and NMN supplements

    Life Extension

    US

    Ranked #3 · 8.2 · NR and NMN supplements

    Why we picked it: It sells NR and NMN products, including NAD+ Cell Regenerator NR, through its supplement line.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 4 companies in the nad plus industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

BONTAC

NAD+ ingredient production · CN

9.4
2

MetroBiotech

NAD+ precursor development · US

8.7
3

Life Extension

NR and NMN supplements · US

8.2
4

Thorne

NR and NMN supplements · US

8.2

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 4 companies in the nad plus industry. In Nad Plus Industry Statistics. Gitnux. https://gitnux.org/nad-plus-industry-statistics/#top-companies

report visual · Projection

Global NAD+ supplements market size

Global NAD+ supplements market size grew from $442.1M in 2020 to $840.1M in 2025.

$442.2M
Start
+13.7%
CAGR · 5y
$840.2M
Projected
20202025
source-verifiedpmarketresearch.com2025

04 Statistics

Market Intelligence

Market intelligence ties the 2025 base—$2.8 billion globally and 49.0% Asia-Pacific share—to channel and product-definition decisions used for NAD+ market sizing.

Market size, volume and shipments in the nad plus industry

  • USD 2.8 billion was the estimated global NAD+ supplements market size in 2025, covering nicotinamide adenine dinucleotide supplements by form and distribution channel.[1]
  • USD 1.6 billion was the reported North American NAD+ products market value, with North America holding 43.5% of the global market in the source’s market definition.[2]

Regional split of the nad plus industry

  • Asia-Pacific accounted for 49.0% of global NAD+ supplements revenue in 2025, making it the largest regional market in the source’s definition.[1]
  • China held the largest country share of the global NAD+ supplements market in 2025 under the source’s country-level market segmentation.[1]
  • North America held 43.5% of the global NAD+ products market and was reported as the leading region in the source’s market definition.[2]

05 Statistics

Production & Operations

Production checks highlight claim risk: 22% of 27 U.S.-market products met labeled NAD+ content in HPLC testing through February 2026.

Defects and conformance in the nad plus industry

  • 100% of U.S.-market NAD+ products with label claims above 500 mg per serving failed to meet their label claims in HPLC testing conducted through February 2026.[3]
  • 100% of nine tested U.S.-market NAD+ softgel products had no detectable NAD+ in HPLC testing conducted from August 2024 to April 2025.[3]
  • 48% of 27 U.S.-market NAD+ dietary supplements contained less than 1% of their labelled NAD+ amount, including 11 products with no detectable NAD+, in HPLC testing through February 2026.[3]
  • 22% of 27 U.S.-market NAD+ dietary supplements met or exceeded their labelled NAD+ content in HPLC testing conducted from August 2024 to February 2026.[3]

06 Statistics

Pricing & Finance

Pricing analytics show wide dispersion in unit cost, with the median listed U.S. price at US$0.13 per mg and ranges from US$0.04 to US$0.75 per mg on 19 November 2026.

Prices and price indices for nad plus

  • The median listed U.S. price for single-vial NAD+ products was US$0.13 per mg, based on 186 suppliers tracked on 19 November 2026.[4]
  • Wholesale NAD+ prices were US$16–26 per 500–1,000 mg vial for orders of 5–24 kits, and US$12–19 per vial for orders of 100 or more kits, according to the supplier’s posted schedule.[5]
  • Listed U.S. single-vial NAD+ prices ranged from US$0.04 to US$0.75 per mg on 19 November 2026, covering 186 suppliers tracked by PepFinder.[4]

07 Statistics

Regulation & Risk

Regulation and risk coverage includes multiple FDA-classified NAD+ injection recalls in 2025, including one Class I action for elevated endotoxin levels.

Recalls and safety notices for nad plus

  • 36 units of the NAD Profile Test were recalled in the United States on November 3, 2025 because the product was distributed without premarket approval or clearance; the FDA classified the action as Class II.[6]
  • One nationwide NAD+ injection recall was classified Class II in 2025 for lack of assurance of sterility, covering 50 mg/mL and 100 mg/mL, 10 mL multi-dose vials.[7]
  • One nationwide NAD+ injection recall was classified Class I in 2025 because of elevated endotoxin levels from microbial contamination of sterile products.[8]

Key questions about the nad plus industry

What is the 2026 market size for NAD+ supplements?
The global NAD+ supplements market is estimated at $3.2 billion in 2026.
How fast is the NAD+ supplements market expected to grow from 2026 to 2033?
Grand View Research forecasts the global market to reach $8.5 billion by 2033, implying a 14.8% CAGR from 2026 to 2033.
Which companies lead the nad plus industry?
BONTAC stands out for NAD+ related ingredient manufacturing because it produces NAD, NADH, NMN, NMNH and NR using proprietary enzymatic production methods, while MetroBiotech focuses on NAD+ precursor development since it develops MIB-626 and other proprietary NAD+ precursors for age-related diseases.
What technology or validation patterns matter in product claims?
Label accuracy varies materially: in a 2026 analysis of 27 top-selling Amazon products, 22% met or exceeded their label claim while 48% contained less than 1% of the claimed amount.
How concentrated is the U.S. market, and what does competition center on?
Acuitas Health Analytics characterizes the U.S. market as moderately concentrated, with competition focused on formulation, clinical evidence, pricing and distribution reach.
What are key regulatory and risk issues that affect NAD+ products in the U.S.?
Dietary supplements do not require FDA approval before sale, but the FDA can act against unsafe or misbranded products. Separate actions include Class II and Class I recalls for NAD+ injection sterility and endotoxin levels in 2025.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Nad Plus Industry Statistics. Gitnux. https://gitnux.org/nad-plus-industry-statistics
MLA
Samuel Norberg. "Nad Plus Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/nad-plus-industry-statistics.
Chicago
Samuel Norberg. 2026. "Nad Plus Industry Statistics." Gitnux. https://gitnux.org/nad-plus-industry-statistics.